You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2025

Claims for Patent: 5,006,530

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,006,530

Title:	Certain 7-[2,6-diisopropyl-4-phenyl-5-lower alkoxymethyl-pyrid-3-yl]-3,5-dihydroxy-6-enoates and derivatives useful for treating circulatory diseases
Abstract:	Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula ##STR1## in which A, B, D and E can have varied meanings, X is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--, and R is ##STR2## wherein R.sup.21 denotes hydrogen or alkyl and R.sup.22 denotes hydrogen, denotes alkyl, aryl or aralkyl, or denotes a cation, and their oxidation products.
Inventor(s):	Angerbauer; Rolf (Wuppertal, DE), Fey; Peter (Wuppertal, DE), Hubsch; Walter (Wuppertal, DE), Philipps; Thomas (Cologne, DE), Bischoff; Hilmar (Wuppertal, DE), Petzinna; Dieter (Duesseldorf, DE), Schmidt; Delf (Wuppertal, DE), Thomas; Gunter (Arese, IT)
Assignee:	Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:	07/298,549
Patent Claims:	1. A substituted pyridine of the formula ##STR217## in which B and E are C.sub.1-3 -alkyl of which one may be cyclopropyl, Y--Q-- is CH.sub.3 O--, (H.sub.3 C).sub.3 C(CH.sub.3).sub.2 --Si--O--, ##STR218## C.sub.2 H.sub.5 O--, C.sub.3 H.sub.7 O--, i-C.sub.3 H.sub.7 O--, C.sub.4 H.sub.9 O--, C.sub.5 H.sub.11 --, C.sub.6 H.sub.13 O-- or ##STR219## and R.sup.22 is hydrogen, lower alkyl, phenyl, benzyl or a physiologically tolerable metal or ammonium cation. 2. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-methoxymethyl-pyrid-3- yl]-3,5-dihydroxy-hept-6enoate of the formula ##STR220## 3. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[5-tert.butyldimethylsilyloxymethyl-4-(4-fluorophenyl)2-isop ropyl-6-methylpyrid-3-yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR221## 4. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[3-benzyloxymethyl-4-(4-fluorophenyl)-6-isopropyl-2-methyl-p yrid-5-yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR222## 5. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[5-tert.butyldimethylsilyloxymethyl-2,6-dimethyl-4-(4-fluoro phenyl)pyrid-3-yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR223## 6. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[6-cyclopropyl-2-isopropyl-4-(4-fluorophenyl)-5-methoxymethy l-pyrid-3-yl[3,5-dihydroxy-hept-6-enoate of the formula ##STR224## 7. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-b 5-phenoxymethyl-pyrid-3-yl[-3,5-dihydroxy-hept-6-enoate of the formula ##STR225## 8. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-carboxyethyl-pyrid-3-y ]-3,5-dihydroxy-hept-6-enoate of the formula ##STR226## 9. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-benzylthio-methyl-pyri d-3-yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR227## 10. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-5-ethoxymethyl-4-(4-fluorophenyl)-pyrid-3-y l]-3,5-dihydroxy-hept-6-enoate of the formula ##STR228## 11. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-propyloxymethyl-pyrid- 3-yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR229## 12. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-isopropoxymethyl-pyrid -3-yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR230## 13. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-butyloxymethyl-pyrid-3 -yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR231## 14. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyloxymethyl-pyrid- 3-yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR232## 15. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-hexyloxymethyl-pyrid-3 -yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR233## 16. A compound according to claim 1, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-3-(4-fluorobenzyloxymethyl)-4-(4-fluorophen yl)-pyrid-5-yl]-3,5-dihydroxy-hept-6-enoate of the formula ##STR234## 17. A composition for inhibiting cholesterol biosynthesis and HMG-CoA reductase comprising an amount effective therefor of a compound according to claim 1 and a pharmaceutically acceptable diluent. 18. A method of treating a patient afflicted with hyperlipoproteinaemia, lipoproteinaemia or arterioschlerosis which comprises administering to such patient and amount effective therefor of a compound according to claim 1. 19. The method according to claim 18, wherein such compound is methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-methoxymethyl-pyrid-3- yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[5-tert.butyldimethylsiloxymethyl-4-(4-fluorophenyl)-2-isopr opyl-6methyl-pyrid-3-yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[3-benzyloxymethyl-4-(4-fluorophenyl)-6-isopropyl-2-methyl-p yrid-5-yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[5-tert.-butyldimethylsilyloxymethyl-2,6-dimethyl-4-(4-fluor ophenyl)pyrid-3-yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[6-cyclopropyl-2-isopropyl-4-(4-fluorophenyl)-5-methoxymethy l-pyrid-3-yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-phenoxymethyl-pyrid-3- yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-carboxymethyl-pyrid-3- yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-benzothio-methyl-pyrid -3-yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-5-ethoxymethyl-4-(4-fluorophenyl)-pyrid-3-y l]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-propyloxymethyl-pyrid- 3-yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-isopropoxymethyl-pyrid -3-yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-butyloxymethyl-pyrid-3 -yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyloxymethyl-pyrid- 3-yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-4-(4-fluorophenyl)-5-hexyloxymethyl-pyrid-3 -yl]-3,5-dihydroxy-hept-6-enoate, methyl erythro-(E)-7-[2,6-diisopropyl-3-(4-fluorobenzyloxymethyl)-4-(4-fluropheny l-pyrid-5-yl]-3,5-dihydroxy-hept-6-enoate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.